{"protocolSection":{"identificationModule":{"nctId":"NCT00188812","orgStudyIdInfo":{"id":"03-0725-AE"},"secondaryIdInfos":[{"id":"E2020-A001-320"}],"organization":{"fullName":"University Health Network, Toronto","class":"OTHER"},"briefTitle":"Safety of Donepezil in Patients With Dementia Associated With Cerebrovascular Disease","officialTitle":"Open-Label, Multicentre, One Year Extension of the Evaluation of the Safety of Donepezil Hcl in Patients With Dementia Associated With Cerebrovascular Disease"},"statusModule":{"statusVerifiedDate":"2005-09","overallStatus":"COMPLETED","startDateStruct":{"date":"2004-05"},"completionDateStruct":{"date":"2005-08"},"studyFirstSubmitDate":"2005-09-12","studyFirstSubmitQcDate":"2005-09-12","studyFirstPostDateStruct":{"date":"2005-09-16","type":"ESTIMATED"},"lastUpdateSubmitDate":"2009-01-09","lastUpdatePostDateStruct":{"date":"2009-01-12","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"University Health Network, Toronto","class":"OTHER"},"collaborators":[{"name":"Eisai Inc.","class":"INDUSTRY"}]},"descriptionModule":{"briefSummary":"one year extension study following a previous double-blind study to evaluate safety of the drug","detailedDescription":"A one year extension study for patients who completed E2020-A001-319. Patients will receive 5my donepezil daily for the first 8 weeks and will be assessed by the incidence of advere events, changes in physical exams, ECG and clinical lab determinations. The results will be assessed 6 timues during the year. After 8 week, the investigator may increase the dose to 10mg/day if the patient if the patients show satisfactory tolerability. Six psychometric scales will also be evaluatd."},"conditionsModule":{"conditions":["Dementia Associated With Cerebrovascular Disease"],"keywords":["dementia","stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}}},"armsInterventionsModule":{"interventions":[{"type":"DRUG","name":"donepezil hcl"}]},"outcomesModule":{"primaryOutcomes":[{"measure":"safety assessments"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* must have completed previous study E2020-A001-319\n\nExclusion Criteria:\n\n* absence of a reliable caregiver\n* clinically significant medical condition\n* recent TIA","sex":"ALL","minimumAge":"45 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Karl Farcnik, MD FRCP(C)","affiliation":"University Health Network, Toronto","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Toronto Western Hopital","city":"Toronto","state":"Ontario","zip":"M5T 2S8","country":"Canada","geoPoint":{"lat":43.70011,"lon":-79.4163}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000003704","term":"Dementia"},{"id":"D000002561","term":"Cerebrovascular Disorders"}],"ancestors":[{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000019965","term":"Neurocognitive Disorders"},{"id":"D000001523","term":"Mental Disorders"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M6594","name":"Dementia","asFound":"Dementia","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","asFound":"Cerebrovascular Disease","relevance":"HIGH"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M21526","name":"Neurocognitive Disorders","relevance":"LOW"},{"id":"M4505","name":"Mental Disorders","relevance":"LOW"},{"id":"M14163","name":"Psychotic Disorders","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BXM","name":"Behaviors and Mental Disorders"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077265","term":"Donepezil"}],"ancestors":[{"id":"D000002800","term":"Cholinesterase Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000018678","term":"Cholinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000018697","term":"Nootropic Agents"}],"browseLeaves":[{"id":"M1721","name":"Donepezil","asFound":"Intranasal","relevance":"HIGH"},{"id":"M5730","name":"Cholinesterase Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M20448","name":"Cholinergic Agents","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"},{"id":"M20464","name":"Nootropic Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"NootAg","name":"Nootropic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}